Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-20

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata

NCT01246284

Alopecia Areata

COMPLETED NA

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT00484679

Alopecia Areata

COMPLETED PHASE2

Intralesional Steroids in the Treatment of Alopecia Areata

NCT01898806

Alopecia Areata

TERMINATED PHASE4

Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata

NCT02684123

Alopecia Areata

COMPLETED NA

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432

Alopecia Areata

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intralesional Triamcinolone

Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg/mL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL

Group Type ACTIVE_COMPARATOR

Candida Albicans Antigen Injection

Intervention Type DRUG

subcutaneous administration of Candida albicans antigen

Candida albicans antigen

Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches

Group Type EXPERIMENTAL

Candida Albicans Antigen Injection

Intervention Type DRUG

subcutaneous administration of Candida albicans antigen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Candida Albicans Antigen Injection

subcutaneous administration of Candida albicans antigen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of alopecia areata
* SALT score of less than 50% extension
* Has not received any topical or systemic treatment in the last month
* Signed informed consent

Exclusion Criteria

* Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
* Pregnancy or breast-feeding
* Patients in medications that could cause hair loss as side-effects

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No